Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2016

We invite all media representatives to attend the daily press conferences, which will be held during ESMO 2016

Venue: Press Conference Room
Bella Center, Copenhagen, Denmark

Download the ESMO 2016 Press Conference Programme

Press Conference Schedule & Programme*

Date & Time

Conference

Friday 7 October 10:30-11:30

Opening Press Conference

Saturday 8 October 08:15-09:00

Press Conference 1: Late Breaking Trials

Sunday 9 October 08:15-09:00

Press Conference 2: Late Breaking Trials

Monday 10 October 08:15-09:00

Press Conference 3: Late Breaking Trials

Tuesday 11 October 08:15-09:00

Q&A for Press

Opening Press Conference: Friday, 7 October, 10:30-11:30

Moderator: Solange Peters

  • Prof Solange Peters, Chair ESMO Press Committee: Overview of ESMO Press Programme
  • Prof Ulrik Lassen, ESMO Local Officer Denmark
  • Andrés Cervantes, Chair ESMO 2016 Scientific Programme: Scientific Programme Highlights
  • Dr Lidija Kandolf-Sekulovic: 13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe
  • Prof Josep Tabernero, ESMO President Elect: ESMO initiatives for equal access to treatment
  • Prof Fortunato Ciardiello, ESMO President: ESMO vision for integrated care
  • Prof Solange Peters: Q&A

Press Conference 1: Saturday, 8 October 2016 , 08:15-09:00

 Moderator: Evandro De Azambuja

  • LBA1_PR: First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Monaleesa 2. Gabriel Hortobagyi
  • LBA2_PR: Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Alexander Eggermont
  • LBA3_PR: A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Mansoor Raza Mirza

Press Conference 2: Sunday, 9 October 2016, 08:15-09:00

Moderator: Stefan Zimmermann

  • LBA8_PR: KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Martin Reck
  • LBA42_PR: Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study.  Giorgio Scagliotti
  • LBA44_PR: Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. Fabrice Barlesi
  • LBA 2949_PR: Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: Keynote-021 cohort g. Corey Langer 

Press Conference 3: Monday, 10 October, 08:15-09:00

Moderator: Dirk Arnold

  • LBA9_PR: Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Karim Fizazi
  • LBA11_PR: Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) Alain Ravaud
  • LBA30_PR: CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Toni Choueiri
  • LBA6_PR: Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. Alessandro Gronchi

Congress highlights. Q&A for Press: Tuesday, 11 October, 08:15-9:00

  • Prof Solange Peters, Chair ESMO Press Committee
  • Prof Andrés Cervantes, Chair ESMO 2016 Scientific Programme

*Subject to changes

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings